ORIG3N, Inc. and Kangstem Biotech announced that they have begun a scientific collaboration to study the utility of induced neural stem cells (iNSC) in disease modeling. As part of the collaboration, Kangstem Biotech will provide iNSCs to ORIG3N for use in its disease-modeling platform. Kangstem Biotech has developed a novel approach to generating patient-specific iNSCs directly from skin fibroblasts. The iNSCs can be further differentiated into different neural-cell types for use in therapies and drug screening for neurological disorders. ORIG3N will leverage in-house capabilities to study iNSCs with the goal of advancing the use of Kangstem's iNSCs in disease modeling applications. ORIG3N is transforming the future of medicine by using Nobel Prize-winning technology to reprogram blood samples into induced pluripotent stem cells, which are then used to grow different cell types including neurons, heart cells and liver cells. These cells offer a powerful tool for accurate disease modeling and drug-discovery research.